AX-2024-004131 · Semax · WWB lot WWB-2308-N1754

Section 1

Results

Measured against the index acceptance specification for the neuroactive and cognitive peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 28 min gradient, 214 nm	99.69	% area	≥ 98.5	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.31	% area	≤ 1.5	PASS
Largest single impurity	RP-HPLC — Met1 sulfoxide (+16 Da)	0.14	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	813.3541	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	813.3555	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	+1.7	ppm	± 15	PASS
Peptide content	not ordered on this submission	not determined	—	required to check label claim	NOT TESTED
Water content	Karl Fischer, coulometric, duplicate	6.09	%	≤ 12.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	6.99	%	≤ 10.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.40	%	—	NOT TESTED
Endotoxin	kinetic chromogenic LAL	0.64	EU/mg	≤ 5.0	PASS
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Clear, colourless, no visible particulates	—	clear, no visible particulates	PASS
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	4.69	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 28 min gradient	6.53	min	6.63 ± 0.25 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.39	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	69,648	—	≥ 20,000	PASS
Resolution to nearest impurity	vs diketopiperazine (−18 Da)	1.47	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 28 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 69,648, and skew follows the reported asymmetry factor of 1.39. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.14 % impurity against a 99.69 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Semax — main peak	6.53	4,845,243	99.69	—
2	Met1 sulfoxide (+16 Da)	6.19	6,804	0.14	+15.995
3	N-acetyl semax (+42 Da)	6.92	4,860	0.10	+42.011
4	des-Met (−131 Da)	6.72	2,430	0.05	-131.040
5	diketopiperazine (−18 Da)	6.68	972	0.02	-18.011
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 813.3541 Da, computed from C37H51N9O10S. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 813.3555 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
2+	407.6843	407.6850	0.0007	58.2
1+	814.3614	814.3628	0.0014	100.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.90	99.69	divergence +0.39 pp vs batch median
Total impurities (% area)	0.10	0.31
Largest single impurity (% area)	not stated	0.14
Water (%)	3.7	6.09
Counter-ion (%)	not stated	6.99
Peptide content (%w/w)	99.0	not determined
Endotoxin (EU/mg)	not stated	0.64
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Supplier-supplied
Evidentiary weight: Weaker evidence. Read with the caveat below.
Chain of custody: Supplier despatch → laboratory direct (courier, cold pack, 7 d) → assay. Submitter did not handle the vial.
Assay date: 25 Jan 2024
Submitted to the index: 07 Feb 2024
Laboratory: PeptideMeter, Tallinn, Estonia
Method basis: 28 min gradient · high-resolution MS
Verification status: VERIFIED

What this report does not establish

How much of the named compound is in the vial. Peptide content was not determined, so recovered mass cannot be calculated and the label claim cannot be checked.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations

No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.

Section 7

Related records

Same batch — lot WWB-2308-N1754 n=14

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2024-004119	WWB-2308-N1754	VendorInvestigate	2024-Q1	98.88	5.42	99.4	Buyer-sourced	0	PASS
AX-2024-004120	WWB-2308-N1754	PeptideMeter	2024-Q1	99.33	5.12	—	Supplier-supplied	1	MARGINAL
AX-2024-004121	WWB-2308-N1754	VendorInvestigate	2024-Q1	98.89	4.92	96.0	Buyer-sourced	0	PASS
AX-2024-004122	WWB-2308-N1754	Janoshik	2024-Q1	99.36	5.61	91.6	Supplier-supplied	1	MARGINAL
AX-2024-004123	WWB-2308-N1754	PeptideMeter	2024-Q1	99.02	5.09	106.7	Supplier-supplied	1	MARGINAL
AX-2024-004124	WWB-2308-N1754	Nordanalyt	2024-Q1	99.69	4.89	—	Supplier-supplied	1	MARGINAL
AX-2024-004125	WWB-2308-N1754	Janoshik	2024-Q1	99.66	5.74	91.6	Supplier-supplied	1	MARGINAL
AX-2024-004126	WWB-2308-N1754	Janoshik	2024-Q1	99.77	5.49	88.8	Supplier-supplied	2	MARGINAL
AX-2024-004127	WWB-2308-N1754	Janoshik	2024-Q1	99.22	5.74	94.7	Supplier-supplied	1	MARGINAL
AX-2024-004128	WWB-2308-N1754	Janoshik	2024-Q1	99.93	5.03	106.9	Supplier-supplied	1	MARGINAL
AX-2024-004129	WWB-2308-N1754	Janoshik	2024-Q1	99.93	5.66	94.6	Supplier-supplied	1	MARGINAL
AX-2024-004130	WWB-2308-N1754	Janoshik	2024-Q1	99.74	5.73	—	Supplier-supplied	1	MARGINAL
AX-2024-004132	WWB-2308-N1754	Janoshik	2024-Q1	99.13	5.11	94.6	Laboratory-retained	0	PASS

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Semax records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-042368	HJ	HJ-2603-V4363	Nordanalyt	2026-Q3	99.17	7.26	106.3	Supplier-supplied	1	MARGINAL
AX-2026-042367	HJ	HJ-2603-V4363	Kestrel	2026-Q3	99.10	6.78	93.9	Supplier-supplied	1	MARGINAL
AX-2026-042260	Homopeptide	HOMO-2605-S1342	Medutest	2026-Q3	99.44	6.06	92.4	Laboratory-retained	1	FAIL
AX-2026-042370	HJ	HJ-2603-V4363	Janoshik	2026-Q3	98.94	7.16	104.0	Supplier-supplied	1	MARGINAL
AX-2026-042369	HJ	HJ-2603-V4363	Janoshik	2026-Q3	99.26	7.67	95.0	Supplier-supplied	1	MARGINAL
AX-2026-041947	TFC	TFC-2602-F4591	Nordanalyt	2026-Q2	99.29	8.98	92.3	Supplier-supplied	0	PASS
AX-2026-041940	TFC	TFC-2602-F4591	Janoshik	2026-Q2	99.06	8.38	98.8	Buyer-sourced	0	PASS
AX-2026-043141	SSA	SSA-2604-L7628	Kestrel	2026-Q2	98.84	8.58	93.2	Supplier-supplied	2	MARGINAL

Other recent WWB records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041275	Liraglutide	WWB-2607-X2189	Nordanalyt	2026-Q3	99.61	5.03	97.3	Supplier-supplied	0	PASS
AX-2026-041387	BPC-157	WWB-2606-H3906	Janoshik	2026-Q3	98.95	4.64	—	Laboratory-retained	1	MARGINAL
AX-2026-041334	Semaglutide	WWB-2606-N3192	Janoshik	2026-Q3	98.83	5.04	—	Supplier-supplied	1	MARGINAL
AX-2026-041337	Semaglutide	WWB-2606-N3192	Nordanalyt	2026-Q3	98.96	4.81	—	Supplier-supplied	1	MARGINAL
AX-2026-041385	BPC-157	WWB-2606-H3906	Medutest	2026-Q3	99.31	4.31	—	Supplier-supplied	1	MARGINAL
AX-2026-041390	BPC-157	WWB-2606-H3906	Medutest	2026-Q3	99.47	4.84	99.3	Supplier-supplied	1	MARGINAL
AX-2026-041386	BPC-157	WWB-2606-H3906	VendorInvestigate	2026-Q3	99.32	4.88	99.2	Buyer-sourced	1	MARGINAL
AX-2026-041335	Semaglutide	WWB-2606-N3192	Janoshik	2026-Q3	99.55	4.55	100.5	Supplier-supplied	1	MARGINAL